Abstract:Introduction. Influenza and acute respiratory viral infection (hereinafter – ARVI) are serious diseases that affect up to 500 million people worldwide every year. From 27.3 to 41.2 million people are registered annually in Russia. Thus, the urgent task is to develop new effective drugs aimed at the prevention and treatment of the above diseases. The drug composition for intranasal use based on aminocaproic acid with antiviral activity and a copolymer of N-vinylpyrrolidone and 2-methyl-5-vinylpyridine with a proven immunostimulating action was developed. Aim. Study of the antiviral activity of the complex drug composition with aminocaproic acid and a copolymer of N-vinylpyrrolidone and 2-methyl-5-vinylpyridine. Materials and methods. To reach this goal, preparations with different ratios of active substances were used to identify the best efficacy. The study was conducted in comparison with the known drug zanamivir. Antiviral activity was studied against influenza A/Puerto Rico/8/34 (H1N1) virus in white outbred mice upon nasal administration of the test samples. The activity evaluation of the studied drugs was carried out according to the weight values and the death dynamics control and experimental groups of animals. Infectious activity of the virus in the lung tissue of animals was assessed on day 5 after infection by titration on a culture of MDCK cells in a nutrient medium MEM. Virus titer was expressed in logarithm of 50% of the virus experimental infectious dose (lg TCID 50 ) per 200 μl of medium. Results and discussion. Based on the data obtained during the study of the weight values dynamics and the dynamics of animal death, the drug showed a maximum antiviral activity with a 2:1 ratio of active substances, which is confirmed by the data on viral activity in the lungs of animals, the virus titer was 1.9±0.3 (p=0.616) lg TCID 50 /0.2 ml. Conclusion. Antiviral activity of the complex preparation based on aminocaproic acid and N-vinylpyrrolidone and 2-methyl-5-vinylpyridine copolymer was studied, the most effective ratio of active substances was found, it is 2:1. Thus this complex preparation with a ratio of active substances 2:1 reduced the viral load level in the lung tissue of infected mice by more than two times relative to the control group. Therefore, this combination of active substances can be used to develop a promising drug for nasal use as treatment and prevention of influenza and ARVI.

Combined antiherpetic effect of complex preparation "Viferon-eye drops" and modified nucleosides

Combined Effect of Basic Antiherpetic Drugs with a New Inhibitor of the Terminase Complex of Herpes Simplex Virus Type 1 in Vero Cell Cultures

The Topical Novel Formulations of Interferon α-2в Effectively Inhibit HSV-1 Keratitis in the Rabbit Eye Model and HSV-2 Genital Herpes in Mice

Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1

Development and characterization of formulations based on combinatorial potential of antivirals against genital herpes

Experience in the Use and Evaluation of the Therapeutic Efficacy of a Drug Based on Para-Aminobenzoic Acid in the Complex Therapy of Herpesvirus Conjunctivitis and Keratitis

Phamacodynamic Study on the Anti-viral Effects in Vitro and in Vivo of Eye Drop Prepared by Mixed Extract of Heartleaf Houttuynia and Lonicera Japonica

IN VITRO INfIBITION OF HHV-1 REPLICATION BY INOSINE PRANOBEX AND INTERFERON-α

The Antiviral Activity Study of Complex Drug with Aminocapronic Acid for Prevention of Influenza and ARVI

[Experimental Study of Suppression of Reactivation of Herpes Simplex Virus Type 1 by Cyclooxygenase 2 Inhibitor with Acyclovir].

Adenovirus-mediated RNA interference against herpes simplex virus infection in vitro

Antiherpetic activities of acidic protein bound polysacchride isolated from Ganoderma lucidum alone and in combinations with acyclovir and vidarabine

Synthesis of LAVR-289, a new [(Z)-3-(acetoxymethyl)-4-(2,4-diaminopyrimidin-6-yl)oxy-but-2-enyl]phosphonic acid prodrug with pronounced antiviral activity against DNA viruses

Effect of Acyclovir Solid Lipid Nanoparticles for the Treatment of Herpes Simplex Virus (HSV) Infection in an Animal Model of HSV-1 Infection

Antiviral activity of temporin-1CEb analogues against gingival infection with herpes simplex virus type 1

Efficacy of 17997 Eye Drops in Different Concentrations on Experimental Rabbit Herpes Simplex Keratitis

Effects of recombinant IFN α-2b suppository on herpes simplex viruses

Enhanced synergistic antiviral effects of thermally expanded graphite and copper oxide nanosheets in the form of a novel nanocomposite against herpes simplex virus type 1

Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection

Combination of ganciclovir and trifluridine prevents drug-resistance emergence in HSV-1

Antiviral Activity of Nitazoxanide and Miltefosine Against FeHV-1 In Vitro